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Abstract
Background: Long noncoding RNAs (lncRNAs) are more than 200 nucleotides in length and lack transcriptional
ability. The biological function of lncRNAs in oral squamous cell carcinoma (OSCC) remains unclear. The aim of
this study was to identify the dysfunction of lncRNA in OSCC.
Results: We analyzed the transcriptome profiles of human OSCC tissues and paired adjacent normal tissues from two
patients through a next-generation sequencing approach. A total of 14 lncRNAs were upregulated (fold change ≥3)
and 13 were downregulated (fold change ≤−3) in OSCC tissues compared with the adjacent normal tissues. SOX21-
AS1 was subjected to further analysis, revealing that the expression levels of SOX21-AS1 significantly decreased in
OSCC compared with the adjacent normal tissue. The promoter activity of SOX21-AS1 was obviously suppressed by in
vitro methylation. The DNA methylation status of the SOX21-AS1 promoter was analyzed using combined bisulfite
restriction analysis, revealing that the aberrant promoter hypermethylation of SOX21-AS1 was observed frequently
in OSCC tissues. The effects of SOX21-AS1 on cell proliferation and invasion were examined through transient
transfection. Our data showed that SOX21-AS1 could significantly suppress oral cancer cell growth and invasion.
Furthermore, the low expression level of SOX21-AS1 was significantly correlated with an advanced stage (P = 0.047),
large tumor size (P = 0.033), and poor disease-specific survival in OSCC patients (P = 0.002).
Conclusions: SOX21-AS1 was identified as susceptible dysfunction correlated with promoter hypermethylation in
OSCC. Low SOX21-AS1 expression may be an adverse prognostic biomarker for OSCC.
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Background
Oral cancer is one of the most common cancers in devel-
oping countries and occurs in the anterior tongue, cheek,
floor of the mouth, gingiva, and other parts of the oral
cavity [1]. Oral squamous cell carcinoma (OSCC) is the
most common oral cancer and 300,400 incident cases and
145,400 deaths have been reported worldwide [2]. Betel
quid chewing, tobacco smoking, and alcohol drinking
contribute to the increasing incidence and mortality rates
of oral cancer [3].
Long noncoding RNAs (lncRNAs) are over 200 nucleo-
tides in length and lack transcriptional ability [4]. Some
lncRNAs, such as transfer RNAs (tRNAs), ribosomal
RNAs (rRNAs), and spliceosomal RNAs, are crucial for
maintaining normal cellular mechanisms [5]. Except for
these functional lncRNAs, most lncRNAs have been fre-
quently considered functionless sequences [6–8]. Recently,
lncRNAs have been reported as crucial for regulating cell
development, growth, cell cycles, and cancer metastasis
in human cancer [9]. Several aberrant lncRNAs were
identified from high-throughput profiles and were asso-
ciated with OSCC progression [10]. Fang et al. reported
that urothelial cancer associated 1 (UCA1) is an overex-
pression in tongue squamous cell carcinomas (TSCCs)
and may play an oncogenic role in tumorigenesis [11].
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Jia et al. [12] reported that the loss of miR-26a expres-
sion resulted in MEG3 downregulation in TSCC tissues
compared with adjacent normal tissues. Low MEG3
expression was highly correlated with poor prognosis of
patients. Furthermore, MEG3 overexpression in SCC-
15 and CAL27 cells inhibited cell proliferation and cell
cycle progression and promoted apoptosis [12]. Onco-
genic lncRNA, HOX transcript antisense RNA (HOTAIR),
was significantly upregulated in OSCC, and the upregu-
lated expression was associated with poor survival and
metastasis. HOTAIR knockdown can suppress oral
cancer cell proliferation, colony formation, cell migra-
tion, and invasion [13]. However, the role of lncRNA
remains largely unknown, and the detailed mechanisms
and functions of dysfunctional lncRNAs in OSCC have
not yet been fully elucidated. On the basis of the ana-
lysis of the expression profile of two pairs of OSCC tis-
sue samples, as well as the experimental studies of two
OSCC cell lines and 86 pairs of OSCC tissue samples in
this study, we determined that SOX21-AS1 expression
was silenced with an aberrant methylation promoter;
moreover, the low expression was highly correlated
with poor prognosis of patients with OSCC.
Results
Long noncoding RNAs identified in OSCC tissues through
next-generation sequencing
Transcriptome profiles were comprehensively analyzed
on laser capture microdissected tumors and corre-
sponding adjacent normal tissues from two OSCC
patients through a next-generation sequencing (NGS)
approach. More than 30 million clean reads were iden-
tified, and >84% clean reads were mapped to human
reference genes in four individual libraries. After the
clean reads were mapped to the genome, over 560
expressed lncRNA genes were detected in four individ-
ual libraries (reads per kilobase per million [RPKM] > 1)
(Additional file 1: Table S1). Dysregulated lncRNAs
were selected from two OSCC patients and were highly
expressed (RPKM of normal + RPKM of tumor > 5), and
the fold change of RPKM was >3 or <−3 as those of
tumor tissues compared with normal tissues. Our data
revealed that 109 lncRNAs were dysregulated (fold
change ≥3 or <−3) in tumor tissues compared with nor-
mal tissues from patient 1; among these lncRNAs, 71
and 38 were upregulated and downregulated, respect-
ively. In addition, 185 lncRNAs were differentially
expressed in patient 2; 96 and 89 of these lncRNAs
were upregulated and downregulated, respectively.
Combining the two profiles revealed that 14 lncRNAs
were significantly upregulated (fold change ≥3), and 13
lncRNAs were downregulated (fold change ≤−3) in
OSCC tissues compared with adjacent normal tissues
(Fig. 1 and Table 1).
DNA methylation-silenced SOX21-AS1 expression in oral
cancer cells
Our previous studies have mainly focused on DNA
methylation regulating noncoding RNA expression in
human cancer [14–17]. Therefore, we sought to deter-
mine whether DNA hypermethylation silences lncRNA
expression in oral cancer. Because a CpG-rich region is
located upstream of SOX21-AS1, we investigated
SOX21-AS1 further. SOX21-AS1 is a 2986-bp long
noncoding RNA, which shares a bidirectional promoter
with SOX21 at human chromosome 13q32.1. SOX21
and SOX21-AS1 share a head-to-head promoter, which
is also conserved in the mouse genome. Furthermore, a
CpG-rich region is located upstream of SOX21-AS1 and
SOX21 (Fig. 2a), implying that their transcriptional
activity may be controlled through DNA methylation.
Our profiles revealed that SOX21 and SOX21-AS1 are
simultaneously downregulated in OSCC tissues com-
pared with paired adjacent normal tissues (Fig. 2b).
Mitchell et al. reported that methylation of the sense
SOX21 was markedly lower in nonneoplastic colorectal
tissues than in colorectal tumors and adenomas [18].
Therefore, we investigated whether SOX21 and SOX21-
AS1 were silenced by aberrant DNA methylation in
OSCC cell lines. After 5-Aza-dC treatment, SOX21-
AS1 and SOX21 expression was increased in the SAS
Fig. 1 Flowchart for identifying abnormal lncRNA candidates
through NGS. The OSCC specimens from two patients were
stained using H&E staining. Normal and OSCC tissues were
carefully separated and collected through microdissection. Total
RNAs were extracted, and the transcriptome profiles were analyzed
using NGS. Comparison of the lncRNA expression profiles between
the tumor and normal samples in the filtering steps are as follows:
(1) fold change ≥3 or <−3 and (2) sums of RPKM in normal and
tumor tissues ≥5. Venn diagrams depicting the number of
upregulated and downregulated lncRNA candidates in two paired
samples of OSCC
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and CAL27 cells (Fig. 2c). The coordinated effects of
histone acetylation and DNA methylation were further
examined. Our data showed synergistic effects on the
increases of SOX21-AS1 and SOX21 expression in the
SAS and CAL27 cells with TSA and 5-Aza-dC cotreat-
ment (Fig. 2c). In addition, a DNA methylation assay
revealed DNA methylation of the CpG-rich region up-
stream of SOX21-AS1 in two oral cancer cell lines
(Fig. 2d). Consequently, TSA and a DNA demethylating
reagent caused marked synergistic activation of SOX21
and SOX21-AS1 genes in oral cancer cells.
To further confirm whether SOX21-AS1 expression was
silenced by DNA methylation, we assessed the promoter
activity of SOX21-AS1 through an in vitro methylation
assay. As shown in Fig. 3a, b, the activity of the PGL-
SOX21-AS1 promoter significantly increased (>500-fold)
compared with that of the negative control, implying
that this DNA fragment exhibited promoter activity.
The pGL-SOX21-AS1 promoter luciferase activity was
almost entirely repressed after complete methylation of
all CpG dinucleotides by M. SssI. However, the pro-
moter constructs of SOX21-AS1 were partially methyl-
ated by M. HhaI or M. HpaII, revealing that the
promoter activity of SOX21-AS1 was only partially
suppressed compared with that of the control groups
(Fig. 3c). The luciferase activity of two CpG dinucleotide-
less promoter constructs, pGL-SRE and pGL-CRE, were
not repressed after complete methylation of all CpG dinu-
cleotides by M. SssI (Additional file 2: Figure S1). Thus,
these data revealed that the transcriptional activity of the
putative promoter of SOX21-AS1 can be repressed using
DNA hypermethylation in oral cancer cells.
Table 1 LncRNA candidates were dysregulation in OSCC
LncRNA N1 (RPKM) T1 (RPKM) Fold change (T1/N1) N2 (RPKM) T2 (RPKM) Fold change (T2/N2)
Upregulation
LINC00152 1.73 7.26 4.12 7.89 117.34 14.87
LOC102724332 1.66 331.85 199.91 0.1 18.3 183
LOC102724977 1.12 161.33 144.04 0.53 8.18 15.43
LOC100507420 0.66 6.77 10.26 0.35 5.35 15.29
LOC102546229 0.1 5.8 58 3.15 46.02 14.61
LOC105379353 1.45 7.61 5.25 2.34 27.73 11.85
LOC654342 2.99 12.74 4.26 1.44 16.05 11.15
LOC105370202 1.09 39.99 36.69 0.63 6.62 10.51
LOC101927797 3.44 13.56 3.94 3.58 20.47 5.72
LOC105373098 0.52 21.34 41.04 3 16.65 5.55
LOC105376387 0.57 5.37 9.42 2.07 10.84 5.24
LOC642934 1.46 15.99 10.95 10.4 40.97 3.94
LOC105376510 1.04 7.78 7.48 17.84 58.28 3.27
LOC105378451 0.29 8.43 29.07 1.77 5.74 3.24
Downregulation
SOX21-AS1 4.47 0.78 0.17 5.43 0.11 0.02
LOC102724112 7.11 2.24 0.32 5.26 0.95 0.18
LOC105379155 9.68 0.84 0.09 7.08 1.1 0.16
LOC105371435 36.74 5.75 0.16 8 0.75 0.09
LOC101928844 14.09 0.92 0.07 11.1 0.84 0.08
LOC105374232 3.69 0.55 0.15 6.24 0.45 0.07
LOC105378948 12.78 3.85 0.30 18.49 1.07 0.06
LOC105379031 4.52 0.35 0.08 5.3 0.1 0.02
LOC105371446 24.63 0.87 0.04 13.02 0.1 0.01
LOC105378132 58.25 2.26 0.04 16.6 0.1 0.01
LOC441178 146.13 5.31 0.04 17.3 0.1 0.01
LOC105372164 15.27 3.76 0.25 19.72 0.1 0.01
LOC101928815 11.7 2.55 0.22 17.15 0.02 0.001
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DNA hypermethylation results in SOX21-AS1 silencing
in OSCC
Our data revealed that SOX21 and SOX21-AS1 expres-
sion was significantly reduced in OSCC tissues compared
with adjacent normal tissues (SOX21: 62 of 86, P < 0.001;
SOX21-AS1: 61 of 86, P < 0.001). Simultaneous downreg-
ulation of SOX21 and SOX21-AS1 was quite frequent in
the 86 OSCC samples (60.5%; 52 of 86; Fig. 4a, b).
Thus, SOX21 expression was significantly correlated with
SOX21-AS1 expression in 86 OSCC tissues (R2 = 0.591,
P < 0.001, Fig. 4c). Previous studies have reported that
combined bisulfite restriction analysis (COBRA) is well
suited for analyzing numerous clinical specimens [19].
Therefore, we further examined the methylation status
of the SOX21-AS1 promoter region by using a COBRA
assay. Our data revealed frequent DNA methylation in
OSCC tissues (CpG1 75.6%, CpG2 60.5%, and CpG3 57%;
Fig. 5a). Tumor-specific hypermethylation of CpG region
2 was frequently observed in oral cancer (36 of 86, 41.9%)
and resulted in decreased SOX21-AS1 expression in
OSCC tissues compared with adjacent normal tissues (25
of 36, 69.4%). In addition, the high methylation status of
CpG region 2 also correlated with low SOX21-AS1 ex-
pression, but CpG regions 1 and 3 were not thus corre-
lated (Additional file 3: Figure S2). Subsequent bisulfite
sequences of three CpG-rich regions in the selected pa-
tient (patient 9) were consistent with those of the COBRA
data (Fig. 5b). Thus, our data revealed that SOX21 and
Fig. 2 DNA methylation regulated expression of SOX21 and SOX21-AS1 in oral cancer cells. a Schema of the locations of the SOX21 and SOX21-AS1
genes from using the UCSC Genome Browser of the human genome GRCh37/hg19 (upper panel) and mouse genome GRCm38/mm10 (lower panel).
Green blocks indicate the upstream CpG islands. b SOX21 and SOX21-AS1 expression was obtained from the NGS data. c SAS and CAL27 cells were
treated with 10 μM 5-Aza-dC for 4 days, and 0.25 μM TSA was added on the third day (upper panel). After the cells were treated with 5-Aza-dC and
TSA, SOX21 and SOX21-AS1 expression was examined using real-time PCR (lower panel). d Schema of the map of the CpG-rich region of SOX21-AS1.
CpG sites are indicated with vertical ticks, and BstU1 or TaqI restriction sites are indicated with vertical arrows, in which the arrowheads indicate the
primers used for analyzing the methylation status of CpG islands (CpG1 248 bp, CpG2 266 bp, and CpG3 276 bp), obtained through COBRA in this
study (upper panel). DNA methylation status of CpG islands in SAS and CAL27 cells were examined using the COBRA assay. Arrows indicate the
unmethylated (u)/methylated (m) alleles (lower panel)
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SOX21-AS1 expression can be silenced using a DNA-
methylated promoter in oral cancer.
SOX21-AS1 suppresses oral cancer cell growth and
invasion
We analyzed the subcellular localization of endogenous
SOX21-AS1, revealing SOX21-AS1 expression accumu-
lating in the nuclei of SAS cells (Additional file 4: Figure
S3A). The predominantly nuclear localization of SOX21-
AS1 might escape RNA interference-silencing machin-
ery, which is the main action in the cytoplasms of the
cells. Therefore, gain-of-function might be a more effect-
ive approach to determining the biological function of
SOX21-AS1. We constructed a SOX21-AS1 expression
vector consisting of two exons with a total length of
approximately 2.9 kb. The putative biological function of
SOX21-AS1 was examined through transient transfection
of pCMV-SOX21-AS1 into SAS cell lines. After transfec-
tion, the SOX21-AS1 expression levels were significantly
overexpressed (>60-fold increase) compared with the vec-
tor control group (Fig. 6a, b). Overexpression of SOX21-
AS1 in SAS cells could significantly inhibit cancer cell
growth, migration, and invasion (Fig. 6c–h). However, ec-
topic SOX21-AS1 expression did not influence endogen-
ous SOX21 expression, implying that SOX21-AS executes
its biological function through an SOX21-independent
pathway (Additional file 4: Figure S3B).
We made two additional deletion constructs, pCMV-
SOX21-AS1-E1 and pCMV-SOX21-AS1-E2, for determin-
ing which region is responsible for cell growth and motility
inhibition. As shown in Fig. 6a, b, both SOX21-AS1-E1
and SOX21-AS1-E2 were significantly overexpressed (>80-
Fig. 3 Promoter activity of SOX21-AS1 was silenced using in vitro methylation. a Schema of the luciferase constructs containing the putative
promoter of SOX21-AS1 (pGL4.21-SOX21-AS1-P 0–829 bp). b Promoter constructs were transfected into SAS cells for 24 h, and luciferase activity
was examined using the Dual-Glo luciferase reporter assay system kit. The SV40 promoter was the positive control. Relative luciferase activity
was compared using the ratio of Renilla reniformis and firefly luciferase activity. c pGL4.21-SOX21-AS1-P was methylated in vitro by using
M. SssI, M. HpaII, and M. HhaI methylase enzymes. The promoter activity was examined using the luciferase reporter assay
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fold increase) compared with the vector control group.
The effects of SOX21-AS1-E1 and SOX21-AS1-E2 on the
proliferation, migration, and invasion of SAS cells were
then respectively examined after transient transfection.
Our data revealed that ectopic overexpression of SOX21-
AS1-E1 revealed no effect on proliferation or motility abil-
ity in SAS cells. Ectopic SOX21-AS1-E2 expression in SAS
cells significantly suppressed the growth and motility abil-
ity of SAS cells (Fig. 6c–h). To understand the putative
mechanism of SOX21-AS1 suppressed cell growth and
invasion ability, we further examined the epithelial-
mesenchymal transition (EMT) genes and growth-related
genes. As shown in Additional file 4: Figure S3C, the ex-
pression level of E-cadherin was increased, and fibronectin
and cyclin D1 were decreased in SAS cells with SOX21-
AS1 overexpression. However, the details of the mecha-
nisms of SOX21-AS1 suppressed cell growth and invasive
ability remain unclear and require further study.
Correlation between SOX21-AS1 expression and
clinicopathological characteristics
The effects of SOX21 and SOX21-AS1 expression on the
clinicopathologic outcomes of patients were evaluated, re-
vealing that the low SOX21-AS1 expression was signifi-
cantly correlated with the pathological stage (P = 0.047)
and T classification (P = 0.033, Table 2). However, no cor-
relation was observed between SOX21 expression and
clinicopathologic features. We further evaluated the asso-
ciation of SOX21-AS1 expression with survival in OSCC
patients. Kaplan–Meier curves and the Cox regression
analysis revealed that low SOX21-AS1 expression was sig-
nificantly associated with a short disease-specific survival
(log-rank P = 0.013, Additional file 5: Figure S4 and
Table 3). The multivariate Cox regression model revealed
that low SOX21-AS1 expression was significantly corre-
lated with shorter disease-specific survival and disease-
free survival for patients with OSCC (DSS: adjusted haz-
ard ratio 5.66, 95% CI 1.85–17.30, P = 0.002; DFS: adjusted
hazard ratio 2.96, 95% CI 1.14–7.64, P = 0.025, Table 3),
after adjustment for cell differentiation, pathological
stages, and the expression level of SOX21.
Discussion
After the entire human genome was completely se-
quenced in 2003, it was revealed that only approximately
2% of the human genome is used for protein coding
[20]. High-throughput sequencing data revealed that
80–90% of the human genomic DNA is actively pro-
duced by RNA transcripts [20–22]. Most of these tran-
scripts are nonprotein coding genes, including small
RNAs and lncRNAs. In the present study, we compre-
hensively analyzed OSCC profiles by using an NGS ap-
proach, which revealed that the expression of 27
lncRNAs significantly differed between OSCC and the
corresponding adjacent normal tissues (Table 1). Among
lncRNAs, lnc00152 has been reported to play an onco-
genic role in promoting gastric cancer cell growth, mi-
gration, and invasion and in suppressing cell apoptosis
by sponging miR-18a-5p, miR-195-3p, miR-139-5p, and
miR-31-5p expression [23, 24]. In addition, lnc00152
was significantly overexpressed in pancreatic cancer
[25]. However, in-depth biological function and the ef-
fect of dysfunctional lnc00152 on oral cancer remain un-
clear and require further investigation.
In this study, our data revealed that SOX21 and SOX21-
AS1 share a head-to-head promoter, and DNA methylation
of the promoter leads to simultaneous suppression of their
expression in OSCC. Our data showed that SOX21-AS1
expression was increased in oral cancer cells treated with 5-
Aza-dC. An in vitro methylation assay demonstrated that
SOX21-AS1 promoter activity could be suppressed with
complete DNA methylation. However, only the methylation
Fig. 4 SOX21 and SOX21-AS1 expression was silenced using DNA methylation. a, b SOX21 and SOX21-AS1 expression in the 86 pairs of adjacent
normal and tumor tissues examined through real-time PCR. c Correlation coefficients of SOX21-AS1 and SOX21 expression in OSCC
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Fig. 5 Methylation status of promoter regions of SOX21 and SOX21-AS1 in 86 patients with OSCC. a Methylation status of three CpG-rich regions
of the SOX21-AS1 promoter was analyzed in the OSCC genome by using COBRA. Arrows indicate the unmethylated (u)/methylated (m) alleles.
We quantified the DNA fragments by using ImageJ, and the DNA methylation status was calculated according to the digested fragment/
(undigested fragment + digested fragment) (lower panels). b Methylation status of one patient (patient 9) examined using bisulfite sequencing. Each
row represents a single clone for each PCR product. Open and filled squares represent unmethylated and methylated CpG sites, respectively
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Fig. 6 Ectopic SOX21-AS1 expression affected cell growth in oral cancer cells. a Schema of the expression constructs (pCMV-SOX21-AS1, pCMV-SOX21-AS1-
exon1, and pCMV-SOX21-AS1-exon2, respectively). b Relative levels of SOX21-AS1, exons 1 and 2, in the SAS cells were analyzed using real-time PCR after
transiently transfecting pCMV, pCMV-SOX21-AS1, pCMV-SOX21-AS1-exon1, and pCMV-SOX21-AS1-exon2, sequentially. c, d Colony formation assays were
used to examine the SAS cell colonies after transient transfection with the expression constructs for 2 weeks. Cell photographs of a representative experiment
are shown, and the graph was quantified using Ascent. Data are reported as colonies compared with control (means ± SD). e–h The migration and invasion
ability were assessed using the transwell assay in SAS cells. After transfection for 24 h, cells were subjected to the transwell assay for 48 h. Cells were then
stained with crystal violet solution, and the numbers of migrating cells were quantified by counting three fields under a phase-contrast microscope
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status of CpG2 was well correlated with low SOX21-AS1
expression in OSCC, but CpG regions 1 and 3 were not
thus correlated (Additional file 3: Figure S2). These con-
flicting results may be due to two putative reasons: (1) A
COBRA assay does not completely represent DNA
methylation status; (2) DNA methylation is not the only
factor for transcriptional silencing.
A previous study revealed that SOX21 expression was
controlled through DNA methylation and was a suitable
biomarker for colorectal cancer diagnosis [18]. In human
Table 2 The relationship of expression levels of SOX21 and SOX21-AS1 with clinicopathologic data of OSCC patients
Variables SOX21 (n = 86) SOX21-AS1 (n = 86)
Low expression High expression P value Low expression High expression P value
Number (%) Number (%) Number (%) Number (%)
Sex
Female 5 (55.6) 4 (44.4) 1.000a 2 (22.2) 7 (77.8) 0.712a
Male 38 (49.4) 39 (50.6) 27 (35.1) 50 (64.9)
Age
≤50 12 (54.5) 10 (45.5) 0.621b 8 (36.4) 14 (63.6) 0.761b
>50 31 (48.4) 33 (51.6) 21 (32.8) 43 (67.2)
Cancer location
Buccal and other oral mucosal sites 36 (54.5) 30 (45.5) 0.126b 25 (37.9) 41 (62.1) 0.138b
Tongue 7 (35.0) 13 (65.0) 4 (20.0) 16 (80.0)
Cell differentiation
Well 5 (41.7) 7 (58.3) 0.534b 4 (33.3) 8 (66.7) 1.000a
Moderate, poor 38 (51.4) 36 (48.6) 25 (33.8) 49 (66.2)
AJCC pathological stage
I 6 (37.5) 10 (62.5) 0.268b 2 (12.5) 14 (87.5) 0.047b
II, III, IV 37 (52.9) 33 (47.1) 27 (38.6) 43 (61.4)
T classification
T1 6 (35.3) 11 (64.7) 0.176b 2 (11.8) 15 (88.2) 0.033b
T2, T3, T4 37 (53.6) 32 (46.4) 27 (39.1) 42 (60.9)
N classification
N0 32 (50.0) 32 (50.0) 1.000b 20 (31.2) 44 (68.8) 0.683b
N1, N2 11 (50.0) 11 (50.0) 9 (40.9) 13 (59.1)
The italic indicated p value <0.05
aP value was estimated by Fisher’s exact test
bP value was estimated by chi-square test
Table 3 Univariate and multivariate Cox’s regression analysis of SOX21-AS1 expression for disease-specific survival and disease-free





Univariate analysis Multivariate analysis
Hazard ratio 95% CI P value Hazard ratio 95% CI P valuea
Disease-specific survival
SOX21-AS1
High 57 (66.3) 8 1.00 1.00
Low 29 (33.7) 10 3.07 1.21–7.78 0.018 5.66 1.85–17.30 0.002
Disease-free survival
SOX21-AS1
High 57 (66.3) 16 1.00 1.00
Low 29 (33.7) 10 1.60 0.72–3.54 0.249 2.96 1.14–7.64 0.025
The italic indicated p value <0.05
aP values were estimated by multiple Cox’s regression, in which adjusted for cell differentiation (moderate and poor vs well), AJCC pathological stage (stages III
and IV vs stages I and II), and SOX21 (high vs low)
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glioma cells, SOX21 overexpression inhibits SOX2 expres-
sion and induces apoptosis because of the interaction be-
tween SOX21 and SOX2 [26, 27]. Ferletta et al. reported
that the knockdown of SOX2 expression can suppress
SOX21 expression at the protein and mRNA levels in
glioma cells, implying that SOX2 can positively regulate
the transcriptional activity of SOX21 [27]. SOX21 in
combination with SOX2 exerts a tumor-suppressive effect
on carcinogenesis. Although SOX21 and SOX21-AS ex-
pression were reduced simultaneously in OSCC, SOX21
expression does not contribute to the clinical manifesta-
tions of patients with OSCC (Tables 2 and 3). Conversely,
low SOX21-AS1 expression was significantly correlated
with poor clinicopathologic features and a short survival
time of patients with OSCC (Tables 2 and 3).
Conclusions
Although SOX21-AS1 can suppress oral cancer cell
growth and invasion, the details of the underlying
mechanism remain unknown. LncRNAs can modu-
late cellular function through different mechanisms
such as RNA degradation, epigenetic modification,
transcriptional regulation, and an miRNA decoy [28].
We analyzed the subcellular fractionation localization
of SOX21-AS1 in SAS cells (Additional file 4: Figure
S3). Furthermore, a considerable increase in SOX21-
AS1 expression was observed in the nuclei compared
with the cytoplasms. According to its location and
tumor-suppressive role, SOX21-AS1 is probably an
enhancer that reinforces other tumor suppressor
mRNAs or acts as a decoy removing certain tran-
scription factors from binding to the DNA to pre-
vent oncogene transcription. In conclusion, low
SOX21-AS1 expression correlated with its sense gene
SOX21 and can serve as an independent biomarker
for poor prognosis of OSCC. SOX21-AS1 and
SOX21 expression in tumors may be downregulated
through DNA hypermethylation. However, the details
of the biological functions of SOX21-AS1 must be
further evaluated in OSCC.
Methods
Clinical samples
Clinical tissue samples were collected from OSCC patients
who provided signed informed consent and accepted a
surgical operation at the Department of Dentistry and
Department of Otorhinolaryngology, Kaohsiung Veterans
General Hospital. This study protocol was approved by
the Institutional Review Board of Kaohsiung Veterans
General Hospital (Kaohsiung, Taiwan; IRB number
VGHKS14-CT6-18). The total RNA and DNA of the tis-
sues were extracted using the TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the instruction manual.
Next-generation sequencing and analysis
In this study, the transcriptome profiles of paired tumors
and adjacent normal tissue samples from two OSCC pa-
tients were analyzed using an NGS approach; the de-
tailed clinical characteristics of the samples are shown in
Additional file 6: Table S2. High-purity normal and tumor
tissues were individually separated through laser capture
microdissection and were transferred to an RNA extrac-
tion kit (Qiagen, Hilden, Germany) for RNA extraction.
All procedures of the RNA transcriptome were performed
according to the manufacturer protocol from Illumina. Li-
brary construction of all samples was performed using
TruSeq RNA Sample Prep Kits v2 for 50 single-end base
pair sequencing on the Solexa platform. Finally, raw se-
quences were obtained from the Illumina GA Pipeline
software CASAVA version 1.8 and expected to generate
30 million reads per sample. After low-quality data were
filtered, qualified reads were analyzed using TopHat/
Cufflinks for estimating gene expression, which was calcu-
lated as RPKM. For differential expression analyses,
CummeRbund was used for statistically analyzing the gene
expression profiles. The reference genome and gene anno-
tations were retrieved from the Ensembl database.
Cell lines and demethylation treatment
Two human OSCC cell lines, SAS (human tongue SCC)
and CAL27 (human tongue SCC) cell lines, were pro-
vided by Dr. Michael Hsiao (Genomics Research Center,
Academia Sinica, Taipei, Taiwan). The oral cancer cell
lines, SAS and CAL27, were cultured in Dulbecco's
modified Eagle’s medium supplemented with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA, USA) and 1%
penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO,
USA). To examine the role of methylation in the regula-
tion of lncRNA expression, SAS and CAL27 cells were
cultured in the presence or absence of 10 μM 5-aza-2′-
deoxycytidine (5-Aza-dC) for 4 days and treated with
0.25 μM TSA on the third day.
Reverse transcriptase polymerase chain reaction of
lncRNAs
For RT-PCR, 2 μg of total RNA was reverse transcribed
using random primers and SuperScript III reverse tran-
scriptase according to manufacturer instructions (Invitro-
gen, Carlsbad, CA, USA). Gene expression was detected
using an SYBR Green I assay (Applied Biosystems, Foster
City, CA, USA), and lncRNA expression was normalized
to that of GAPDH (△Ct = target lncRNA Ct-GAPDH Ct).
The individual primers used in the present study were as
follows: SOX21-F: GCACAACTCGGAGATCAGCA and
SOX21-R: CCGGGAAGGCGAACTTGTC; SOX21-AS1-
exon1-F: CCGATGGGAAACCCCCAATC and SOX21-
AS1-exon1-R: AACGCTTGCTCAAGCCTCAT; SOX21-
AS1-exon2-F: TCACTTACATGCGCTGCTGA and
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SOX21-AS1-exon2-R: GCCGCAGCATACCAAAAA
GT; GAPDH-F: TGCACCACCAACTGCTTAGC and
GAPDH-R: GGCATGGACTGTGGTCATGAG.
SOX21-AS1 promoter and expression construction
The SOX21-AS1 promoter was amplified using the
promoter-specific primer pairs (SOX21AS1-promoter-
F: ATGAAGCTTCCATGAAGGCGTTCATGGGCCG and
SOX21AS1-promoter-R: ATGAAGCTTAGAGGAAGAC
TCGAGAGGCAGGT). PCR products were digested
with the restriction enzyme HindIII and cloned into the
pGL4.21 luciferase expression vector (Promega, Madison,
WI, USA). Full-length exons 1 and 2 of the SOX21-AS1
PCR products were amplified using individual primer
pairs (exon1-F: ATGGAATTCTCTTCTTGGCTCCGGG
CAGGGTG and exon1-R: ATGAAGCTTCTGAGCCGG
TGCAGAGGGCG; exon2-F: ATGGAATTCGTTTAGG
CGAGTGGAGAGTCCG, and exon2-R: ATGCTCGA
GAATCTTTAGGACAAAACTGAGC). The PCR prod-
ucts were digested with the restriction enzyme EcoRI
and cloned into the pCMV-Tag 2A vector (Stratagene,
La Jolla, CA, USA).
In vitro methylation
We sequentially methylated pGL4-SV40, pGL4-SRE pro-
moter, pGL4-CRE promoter, and pGL4-SOX21-AS1-P in
vitro by using M. SssI, M. HpaII, and M. HhaI methyl-
transferase enzymes (Invitrogen, Grand Island, NY,
USA). A luciferase assay was performed in SAS cells by
using a Dual-Glo luciferase reporter assay system kit
(Promega, Madison, WI, USA) 24 h after transfection.
Combined bisulfite restriction and sequencing analyses
DNA was subjected to bisulfite conversion by using
the EZ DNA Methylation-Gold Kit (Zymo Research
Corporation, Orange, CA, USA). The bisulfite-
converted genomic DNA was used for methylation
analysis of the promoter with the specific methylation
primers. The methylation status of the genomic DNA
of individual samples was examined using TaqI or
BstUI digestion (New England Biolabs, MA, USA).
Furthermore, the PCR products were cloned into the
pJET1.2 vector (Promega, Madison, WI, USA), and
several clones were used for sequencing. The individ-
ual primers used in the present study were as follows:
CpG1-F: ATGAAATTTTTAATAAAATTGGAAAGGT
and CpG1-R: CCAAATAAAA ACAAA AAAACCAA
AC; CpG2-F: GGTTGTTTTTGGGATATTTTAATT




SAS cells were transfected with pCMV-SOX21-AS1,
pCMV-SOX21-AS1-exon1, pCMV-SOX21-AS1-exon2,
and empty vectors by using Lipofectamine® 2000 Reagent
(Invitrogen, Grand Island, NY, USA). For the clonogenic
assay, 2000 transfecting cells were plated onto 6-well
plates for 2 weeks until substantial-sized colonies were
formed. Subsequently, the colonies were analyzed using
crystal violet staining.
Cell migration and invasion assays
The migration and invasion abilities of cells were
assessed in vitro by using a transwell assay. In brief, cells
were resuspended at a density of 4.5 × 105 in 2% fetal
bovine serum and then added to the upper chamber of
the transwells (Falcon, Corning Incorporated, USA)
without Matrigel (BD Biosciences, MA, USA) for the
migration assay or with a Matrigel coating for the inva-
sion assay. Chambers were incubated in a CO2 incuba-
tor at 37 °C for 36–48 h; the remaining cells in the
upper chamber were removed using cotton swabs, and
the cells on the undersurface of the transwells were
fixed in 10% formaldehyde solution. Cells were stained
with crystal violet solution, and the numbers of cancer
cells in three fields were counted under a phase-
contrast microscope.
Statistical analysis
The chi-square test, Fisher exact test, Student t test,
ANOVA, Mann–Whitney U test, and Kruskal–Wallis
one-way ANOVA were used to evaluate the correlation
of each lncRNA expression with different oral tissues or
clinicopathological parameters. For clinicopathologic
outcome and survival analysis, the RNA expression
levels (-delta Ct) of SOX21-AS1 were dichotomized as
low expression and high expression with the cutoff value
(−9.8647) based on a receiver operating characteristic
(ROC) curve analysis. The clinicopathologic outcome is
usually defined as the time of initial diagnosis or surgery.
Disease-specific survival was measured from the time of
the initial resection of the primary tumor to the date of
cancer-specific death or the final follow-up. Disease-free
survival was calculated from the date of the initial resec-
tion of the primary tumor to the date of recurrence or
the final follow-up. In this study, the median time of
follow-up was 25.68 (range, 1.00–68.27) months. The
cumulative survival curves were estimated using the
Kaplan–Meier method, and the survival curves were
compared using the log-rank test. A Cox proportional
hazards model was used for determining independent
predictors of survival by using factors significant in uni-
variate analysis as covariates; P < 0.05 was considered
statistically significant.
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Additional files
Additional file 1: Table S1. The categories of sequence reads in the
four libraries. (DOC 28 kb)
Additional file 2: Figure S1. Promoter activity of CpG dinucleotideless
was examined using in vitro methylation assay. Luciferase activity of CpG
dinucleotide-less promoters was analyzed through in vitro methylation.
(A, B) Schema of the luciferase constructs containing two CpG
dinucleotide-less promoters of pGL-serum-response element and pGL-
cAMP-response element (upper panels). Promoter constructs were meth-
ylated in vitro by using M. SssI methylase enzymes, and luciferase activity
was examined using the
Dual-Glo luciferase reporter assay system kit. (PPT 174 kb)
Additional file 3: Figure S2. The correlation between od SOX21-AS1
expression and DNA methylation status. Correlation between SOX21-AS1
expression and DNA methylation status was examined in OSCC from 86
patients. (PPT 134 kb)
Additional file 4: Figure S3. The cellular localization of SOX21-AS1 and
putative mechanism were examined in SAS cell. (A) Cell-fractioned RNA
was isolated from the nuclei and cytoplasms of SAS cells. Expression
levels of SOX21-AS1 were detected using RT-qPCR. (B) Expression levels
of SOX21 were
examined using real-time PCR after SOX21-AS1 was transfected into
SAS cells. (C) Expression levels of EMT- and cell cycle-relative genes
were examined using a Western blot approach in SAS cells with SOX21-
AS1 overexpression. (PPT 2411 kb)
Additional file 5: Figure S4. Analysis of the prognostic significance of
SOX21-AS1 expression in oral cancer. (A, B) DSS and DSF were compared
according to SOX21-AS1 expression levels in oral cancer tissues. (PPT 239 kb)
Additional file 6: Table S2. The detailed clinical characteristics of two
OSCC patients. (DOC 29 kb)
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